<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02727790</url>
  </required_header>
  <id_info>
    <org_study_id>129/12</org_study_id>
    <secondary_id>HTA6446</secondary_id>
    <nct_id>NCT02727790</nct_id>
  </id_info>
  <brief_title>Effect of Short Peripheral Electrical Stimulation (PES) on Blood Glucose</brief_title>
  <official_title>Effect of Short Peripheral Electrical Stimulation (PES) on Blood Glucose Lowering Action in Type 2 Diabetes Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assaf-Harofeh Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assaf-Harofeh Medical Center</source>
  <brief_summary>
    <textblock>
      The epidemic nature of type 2 diabetes mellitus, along with the downsides of current
      treatments, has raised the need for therapeutic alternatives. The aim of this study is to
      evaluate safety, tolerability, and the glucose-lowering effect of noninvasive peripheral
      electrical stimulation (PES) as an alternative treatment for diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with hypoglycemia, and/ or adverse events that are related to treatment</measure>
    <time_frame>Baseline through 2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of minor side effects related to treatment</measure>
    <time_frame>Baseline through 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in mean interstitial glucose levels measured by CGM</measure>
    <time_frame>Baseline, 1, 2, 5, and 6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>PES Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible patients will receive daily 5 min PES treatment for two weeks. Interstitial glucose will be monitored throughout the study using a FreeStyle Navigator (Abbott Diabetes Care, Alameda, CA) continuous glucose monitor (CGM) System</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Interstitial glucose will be monitored throughout the study using a FreeStyle Navigator (Abbott Diabetes Care, Alameda, CA) CGM System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Stimulator</intervention_name>
    <arm_group_label>PES Treatment</arm_group_label>
    <other_name>BEAC Biomedical Intellistim BE-28TC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with type II diabetes, for at least one year prior to randomization

          -  Body mass index BMI &lt; 35 Kg/m2

          -  Stable glucose lowering drugs regimen for at least one month prior to randomization

          -  Capable of giving informed consent

        Exclusion Criteria:

          -  Pregnancy, or nursing

          -  10&lt; HbA1c &lt; 6

          -  Permanent pacemakers

          -  Metal prosthesis

          -  Resting blood pressure &gt; 160/ 100 mmHg

          -  Skin disease

          -  Treatment with steroids or beta-blockers treatment with psychiatric medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Assaf-Harofeh Medical Center</name>
      <address>
        <city>Zerifin</city>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2016</study_first_submitted>
  <study_first_submitted_qc>March 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2016</study_first_posted>
  <last_update_submitted>June 6, 2016</last_update_submitted>
  <last_update_submitted_qc>June 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

